← All trials
NCT06102512
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2023
- Primary completion
- Jan 11, 2024
- Completion date
- Jan 11, 2024
- First posted
- Oct 26, 2023
- Last posted
- Oct 26, 2023
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- Loxo OncologyCollaborator
- Loxo OncologyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.